SCM
MRNS

Suvretta Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Suvretta Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,073,913
Closed -$8.93M – 115
2024
Q3 		$8.93M Buy
5,073,913
+1,253,901
+33% +$1.75M 0.29% 55
2024
Q2 		$4.47M Sell
3,820,012
-1,288,508
-25% -$3.22M 0.16% 54
2024
Q1 		$46.2M Sell
5,108,520
-237,599
-4% -$2.31M 1.72% 20
2023
Q4 		$58.1M Buy
5,346,119
+141,177
+3% +$1.06M 2.63% 11
2023
Q3 		$41.9M Buy
5,204,942
+1,147,331
+28% +$9.54M 2.26% 13
2023
Q2 		$44.1M Sell
4,057,611
-773,650
-16% -$6.63M 2.36% 12
2023
Q1 		$33.3M Buy
4,831,261
+8,266
+0.2% +$51.8K 1.41% 29
2022
Q4 		$19.2M Buy
4,822,995
+1,285,295
+36% +$6.32M 0.81% 42
2022
Q3 		$23.5M Buy
3,537,700
+26,869
+0.8% +$165K 0.98% 41
2022
Q2 		$17M Buy
3,510,831
+744,831
+27% +$4.53M 0.65% 48
2022
Q1 		$25.9M Buy
2,766,000
+127,225
+5% +$1.26M 0.79% 40
2021
Q4 		$31.3M Buy
2,638,775
+441,349
+20% +$5.1M 0.61% 41
2021
Q3 		$25M Buy
2,197,426
+370,981
+20% +$5.1M 0.42% 46
2021
Q2 		$32.8M Hold
1,826,445
– – 0.49% 46
2021
Q1 		$28.3M Buy
1,826,445
+396,273
+28% +$5.73M 0.42% 51
2020
Q4 		$17.4M Buy
1,430,172
+650,447
+83% +$9.07M 0.25% 55
2020
Q3 		$10M Buy
779,725
+279,725
+56% +$2.41M 0.18% 53
2020
Q2 		$5.08M Buy
+500,000
New +$4.6M 0.11% 56

Other funds holding MRNS

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Suvretta Capital Management's MRNS Position: Q4 2024 in Review

Suvretta Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2024, closing a stake of 5,073,913 shares — an estimated $8.93M sold.

Suvretta Capital Management first reported a position in MRNS in Q2 2020 and held it in 18 quarters. The position peaked at $58.1M in Q4 2023. 53 funds tracked by Wall St. Rank hold MRNS as of Q4 2024.

  • Suvretta Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2024 after selling out during the quarter.
  • Suvretta Capital Management sold 5,073,913 Marinus Pharmaceuticals, Inc shares in Q4 2024, an estimated $8.93M.
  • Suvretta Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q2 2020 and held it in 18 quarters.
  • Suvretta Capital Management's Marinus Pharmaceuticals, Inc position peaked at $58.1M in Q4 2023.
  • 53 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2024.

Based on Suvretta Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.